Rare Disease Dx Challenges Raised; FDA Readies Pharmacogenomic Guidance
This article was originally published in The Gray Sheet
Executive Summary
Pharmacogenomic developers of rare disease diagnostics face a dual difficulty: finding suitable patients and demonstrating a market value to large pharmaceutical firms